Tag Archives: SVVC

Top 10 Heal Care Stocks To Own For 2018

Whether you’re ready for it or not, the marijuana industry is flowering before our eyes. In North America, cannabis research firm ArcView, in partnerships with BDS Analytics, has projected sales growth of 28% through 2021. If this estimate proves accurate, we could be looking at almost $25 billion in annual North American legal weed sales in just a few years.

All eyes are on Canada

Though the entire world has seemingly looked to the U.S. to lead the charge of cannabis progressivism, it’s stepped aside and allowed Canada to grab the reins. Despite 30 U.S. states having legalized marijuana in some capacity, the federal government and Attorney General Jeff Sessions have been unwavering on pot’s Schedule I classification — i.e., wholly illegal, prone to abuse, and having no recognized medical benefits.

Image source: Getty Images.

Top 10 Heal Care Stocks To Own For 2018: Arc Wireless Solutions Inc.(ARCW)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Watts Water Technologies (NYSE: WTS) and ARC Group WorldWide (NASDAQ:ARCW) are both computer and technology companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

  • [By Jim Robertson]

    On Thursday, our Under the Radar Moversnewsletter suggested small cap manufacturing and 3D printing service provider ARC Group WorldWide (NASDAQ: ARCW) as a short trade:

Top 10 Heal Care Stocks To Own For 2018: Computer Programs and Systems Inc.(CPSI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Computer Programs & Systems, Inc. (NASDAQ: CPSI) were down 31 percent to $27.00 after the company posted weaker-than-expected Q2 results.

Top 10 Heal Care Stocks To Own For 2018: Uni-Pixel, Inc.(UNXL)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Uni-Pixel (UNXL) manufactures electronic film products using its proprietary manufacturing process, UniBoss. This stock closed up 7.6% to $16.84 in Monday’s trading session.

    Monday’s Volume: 1.88 million

    Three-Month Average Volume: 1 million

    Volume % Change: 108%

    From a technical perspective, UNXL bounced sharply higher here right off its 50-day moving average of $15.89 with above-average volume. This stock looks to be forming a double bottom chart pattern at $14.91 to $15.16. If that bottom holds, then shares of UNXL could see a continuation of Monday’s upside action.

    Traders should now look for long-biased trades in UNXL as long as it’s trending above $15.16 or $14.91 and then once it sustains a move or close above Monday’s high of $17.53 with volume that hits near or above 1 million shares. If we get that move soon, then UNXL will set up to re-test or possibly take out its next major overhead resistance level at its 200-day moving average of $19.89.

  • [By Lisa Levin]

    Shares of UniPixel Inc (NASDAQ: UNXL) were down 22 percent to $1.63 after the company announced a public offering of newly issued shares of stock. UniPixel plans to offer 5.35 million shares of its own stock at a public offering price of $1.50 per share with the option for its underwriters to purchase up to an additional 802,500 shares.

  • [By Peter Graham]

    Small cap sensor film stockUniPixel Inc (NASDAQ: UNXL) reportedQ1 2017 earnings after the Thursday market close withshares falling both on Thursday and in afterhours trading. UniPixel is not well covered or known by analysts yet and this can make shares volatile. However and last September, we had suggested a long position in the stock based upon technicals by saying:

Top 10 Heal Care Stocks To Own For 2018: Canon, Inc.(CAJ)

Advisors’ Opinion:

  • [By Paul R. La Monica]

    Miscellaneous shorts. Lamensdorf is also betting against Japanese printer and camera giant Canon (CAJ) since he believes the company still hasn’t figured out a way to compete with smartphones.

  • [By Dan Carroll]

    Nikon’s story is similar to what’s plaguing its Japanese rival, Canon (NYSE: CAJ  ) . Canon’s stock has nosedived by 20% year to date, but the stock’s recovered nearly 3% over the past month. Don’t let appearances fool you: The company slashed its full-year sales and profit forecasts back in July, as the worldwide camera market has slumped, and as smartphones continue to take over this aging niche. Canon’s route back to respectability looks like a treacherous climb.

Top 10 Heal Care Stocks To Own For 2018: Aclaris Therapeutics, Inc.(ACRS)

Advisors’ Opinion:

  • [By Chris Lange]

    Aclaris Therapeutics Inc. (NASDAQ: ACRS) saw its shares make a handy gain on Friday after the company announced the pricing of its secondary offering. The company intends to price its 4 million shares at $22.75 per share, with an overallotment option for an additional 600,000 shares. At this price the entire offering is valued up to $104.65 million.

  • [By Peter Graham]

    Small cap hair loss stocks Aclaris Therapeutics (NASDAQ: ACRS), Cytori Therapeutics (NASDAQ: CYTX) and RepliCel Life Sciences (OTCQB: REPCF; CVE: RP) are trying to tap into a big market as currently, there are only two FDA-approved drugs available for the treatment of Androgenetic Alopecia (AGA) -also known as male or female pattern baldness (one of which cannot be used by women). Thus, a significant unmet need exists for a safe andefficacious product especially since its experienced by 70% of men and 40% of women as they age.

Top 10 Heal Care Stocks To Own For 2018: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 10 Heal Care Stocks To Own For 2018: Helios and Matheson Analytics Inc(HMNY)

Advisors’ Opinion:

  • [By Cameron Saucier]

    Helios and Matheson Analytics Inc. (Nasdaq: HMNY) is an information technology company that provides its clients predictive analytics. The company uses big data for most of its software and operates within the financial services, insurance, and healthcare industries. HMNY is up 278% YTD after it announced a strategic merger with a GPS application company, called RedZone Maps. RedZone is known for mapping crime in major cities. News of the merger sent HMNY climbing over 1,000% from $1.11 per share to $13.75 per share over the course of a week. The stock has since fallen to $5.23 per share as of Monday intraday.

  • [By Paul Ausick]

    The subscription service is controlled by Helios & Matheson Analytics Inc. (NASDAQ: HMNY), which owns about 81% of MoviePass stock.

    MoviePass CEO Mitch Lowe commented:

  • [By Lisa Levin] Gainers
    Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate.
    Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination with KEYTRUDA.
    Puma Biotechnology Inc (NASDAQ: PBYI) rose 21.7 percent to $99.75 in pre-market trading as the company disclosed positive PB272 Phase 2 data from TBCRC 022 trial at ASCO17.
    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares rose 20.7 percent to $3.21 in pre-market trading after the company reported that RedZone has acquired all the assets of Trendit including three technology patents.
    Forestar Group Inc. (NYSE: FOR) rose 13.1 percent to $16.05 in pre-market trading after D.R. Horton, Inc. (NYSE: DHI) proposed to buy 75 percent of Forestar Group for $16.25 per share in cash.
    TG Therapeutics Inc (NASDAQ: TGTX) shares rose 12 percent to $15.50 in pre-market trading after the company said Phase 3 GENUINE trial met primary endpoint with TG-1101 + ibrutinib increasing overall response rate by >70 percent versuss ibrutinib alone.
    Gigamon Inc (NYSE: GIMO) gained 10.8 percent to $43.55. Reuters reported that Gigamon is exploring a potential sale.
    BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) rose 8.7 percent to $6.00 in pre-market trading after the company announced Rapivab pediatric sNDA acceptance by the FDA.
    Array Biopharma Inc (NASDAQ: ARRY) rose 7.2 percent to $8.77 in pre-market trading after gaining 5.68 percent on Friday.
    Ehi Car Services Ltd (ADR) (NYSE: EHIC) shares rose 6.4 percent to $10.76 in pre-market trading. eHi Car Services posted Q1 earnings of $0.06 on sales of $89.43 million.
    Skyworks Solutions Inc (NASDAQ: SWKS) rose 5.9 percent to $114.79 in pre-market trading after gaining 0.69 percent on Friday.
    Sorl Auto
  • [By Peter Graham]

    Small cap analytics stock Helios and Matheson Analytics (NASDAQ: HMNY) is thethird most shorted stock on the NASDAQ with short interest of 54.30% according to Highshortinterest.com. Helios and Matheson Analytics is a provider of information technology services and solutions, offering a range of technology platforms focusing on big data, artificial intelligence, business intelligence, social listening, and consumer-centric technology. The Company owns a majority interest in MoviePass Inc., the nation’s premier movie-theater subscription service.Other holdings include RedZone Map, a safety and navigation app for iOS and Android users, and a community-based ecosystem that features a socially empowered safety map app that enhances mobile GPS navigation using advanced proprietary technology.

  • [By Lisa Levin]

    Helios and Matheson Analytics Inc (NASDAQ: HMNY) shares dropped 32 percent to $6.87 after the company reported a common stock offering. The size of the offering was not disclosed. The company said that proceeds from the offering and warrants will be used to increase the company’s ownership stake in MoviePass.

Top 10 Heal Care Stocks To Own For 2018: Mastercard Incorporated(MA)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Visa Inc. (NYSE:V) and MasterCard (NYSE:MA) aren’t the only two players in the credit card and electronic payments space, but they are the biggest and best-known. Both Visa and MasterCard have extended their reach across the globe, and both have high expectations in their trajectories for future growth. Yet after a big push in the stock market that has sent both of these financial stocks to all-time highs, investors need to know which of the two leaders in the card industry is more deserving of their attention. Let’s take a closer look at Visa and MasterCard, comparing them using several different metrics to see which company’s shares are the better buy.

  • [By Matthew Cochrane]

    Keeping these statistics in mind, one can see how marrying these two concepts would be equivalent to finding the Holy Grail of payments. This is how Mastercard Inc (NYSE:MA), clearly one of the giants in the payments space, plans to capture market share and win more card issuer deals by making payments as safe and frictionless as possible.

  • [By John Ballard]

    Partnerships play a crucial role in extending PayPal’s reach to new customers and driving higher engagement. The deal with Visa(NYSE:V) opened the door for partnerships with Mastercard(NYSE:MA), Citigroup(NYSE:C), and Fidelity National Information Services (NYSE:FIS). As a result, more deals will come that will increase PayPal’s relevancy and ubiquity in the mobile payment landscape.

  • [By ]

    Card networks Visa (NYSE: V) and Mastercard (NYSE: MA), which benefit from the same tailwinds, aren’t much better, both with minuscule yields of 0.7%.

  • [By ]

    Mastercard Inc. (MA) announced this week that it plans to employ new blockchain specialists in an upcoming hiring round of 175 technology developers, Coindesk reported. The new tech hires will work from Mastercard’s Ireland office, where its research and development business, Mastercard Labs, is headquartered. The company said the aim of the new hires is to further the development of more efficient payment systems. Last September, Mastercard filed a patent for a blockchain system recording purchase orders, invoices and transaction data. Then in November, the company filed another application for blockchain-based solutions aimed at increasing the speed of transaction settlements.

  • [By WWW.GURUFOCUS.COM]

    For the details of Night Owl Capital Management, LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Night+Owl+Capital+Management%2C+LLC

    These are the top 5 holdings of Night Owl Capital Management, LLCVisa Inc (V) – 231,674 shares, 10.84% of the total portfolio. Shares reduced by 5.42%Mastercard Inc (MA) – 167,458 shares, 9.92% of the total portfolio. Shares reduced by 5.37%Alphabet Inc (GOOG) – 18,613 shares, 8.13% of the total portfolio. Shares reduced by 4.05%Amazon.com Inc (AMZN) – 15,674 shares, 7.32% of the total portfolio. Shares reduced by 3.17%The Priceline Group Inc (PCLN) – 6,970 shares,

Top 10 Heal Care Stocks To Own For 2018: Fox Factory Holding Corp.(FOXF)

Advisors’ Opinion:

  • [By Javier Hasse]

    Fox Factory Holding Corp (NASDAQ: FOXF) was down 1.8 percent after posting a 2.16 percent rise over the day.

    Finally, Groupon Inc (NASDAQ: GRPN) gained 1.3 percent, continuing with the 3.85 percent spike it experienced on Friday trading.

Top 10 Heal Care Stocks To Own For 2018: Radient Technologies (RTI)

Advisors’ Opinion:

  • [By Jim Robertson]

    Shares of small cap natural compound and Cannabinoid extract stock Radient Technologies (CVE: RTI) have been taking off lately as the Company makes further progress commercializing its technology. The Company extracts natural compounds from a range of biological materials using microwave assisted processing (MAP), a patented technology platform which provides superior customer outcomes in terms of ingredient purity, yield and cost. This technology is based on the selective and localized heating of the moisture present in all natural materials using microwaves as the energy source. This gives the Company a technological advantage and expertise in selectively depositing microwave energy into different parts of a biomass’ complicated chemical system form the core of our extraction advantage.

  • [By Bryan Murphy]

    It’s been a long time in the coming, but there’s no denying the tipping point has been reached — cannabinoids are the foundation for a whole new kind of medicine. And, the work-to-date turning cannabis into pharmaceuticals has been very encouraging.

    Problem: While the premise of cannabinoids as drugs has been validated, the science of creating large quantities of pure cannabinoids remains more ineffective than effective. Radient Technologies Inc (CVE:RTI) is about the change that, leveraging a means of extracting a lot of cannabinoid material from a source, and ensuring the highest-level of purity and quality.

    Radient Technologies manufactures natural ingredients for global customers across a range of industries, including food and beverage, nutrition, supplements, pharmaceuticals and cosmetics. Using a proprietary, patented technology, Radient’s products are superior in quality and purity while manufactured at a significantly lower cost than other methods thanks to superior yields and efficiency.

    To fully appreciate the science Radient has developed, however, one must understand the alternative methods currently employed.

    With current approaches to create ingredients from an appropriate source, the material with the target compound or molecule in it is soaked in a solvent, heated, and then over the course of several hours the desired ingredient diffuses into the solvent. After filtration, drying, and other processing, that ingredient is finally isolated and then collected.

    It works, but it’s far from ideal. Aside from the fact that this technique doesn’t work very well at large scale, yields are relatively low. Worse, many undesirable components can still be found in the extract, lowering the quality and purity of the ingredient.

    Radient Technologies uses an ingredient-extraction process called microwave assisted processing, or “MAP,” for short.

    Using its patented MAP process, Radient is able to selectiv

  • [By James E. Brumley]

    Some of the stories about how cannabis has changed lives for the better are nothing less than astounding. Take Illinois resident Darren Miller as an example. In 2015 Miller was diagnosed with lung cancer that was later deemed terminal. Miller underwent chemotherapy, without much hope, but also began using high-THC Indica cannabis oil. Miller is alive today, and arguably shouldn’t be.

    Then there’s Floridian Branden Petro. Not only does Petro suffer epilepsy, he commonly experiences seizures stemming from the condition. Nothing has stopped the seizures as quickly or effectively as 200 milligram worth of THC cannabis oil, administered as a nasal spray. Within 20 seconds of using it, it’s as of the seizure never happened.

    And there are millions of other such (and less dramatic) examples, all pointing in the same direction – cannabis has medical value on multiple fronts. Not facilitating its commercialization is a wasted opportunity.

    It’s a notion that’s far from lost on the people that have built Canadian-based Radient Technologies Inc (CVE:RTI) from the round up, recently inking a deal with supplier of cannabinoid extracts, Aurora Cannabis.

    It’s a real accolade. Aurora is one of the largest licensed producers of medical cannabis under Health Canada’s Access to Cannabis for Medical Purposes Regulations (ACMPR), and recently began construction on an unprecedented 800,000 square foot production facility in Leduc County, Alberta. This facility, known as “Aurora Sky”, is anticipated to be capable of producing in excess of 100,000 kg of high-quality, low-cost marijuana per year.

    In most regards though, Radient Technologies is the big winner of the deal, as the partnership is apt to put its high-tech facility in full demand, helping to advance the advent of cannabis in all its potential glory.

    It’s a rather amazing science, really. Radient Technologies uses an ingredient-extraction process called microwave assisted proc

best stocks to buy now

The New York Times is running its first television ad in seven years during the Oscars Sunday night. The subject? The truth.

The ad begins with voices saying, “The truth is our nation is more divided than ever,” with those words spelled out against a white backdrop. The phrase then changes to “The truth is alternative facts are lies.” The ad repeats different versions of the “The truth is…” as the voices speed up and get louder. It ends with: “The truth is hard” and “The truth is more important now than ever.”

The ad’s mission is to tap into “national dialogue going on right now about facts and the truth” and what that means in today’s world, according to New York Times branding exec David Rubin.

“The idea is to be a part of that discussion about what does it mean to find the truth,” he said. “What does that mean in a world of ‘fake news’? And what is the role of journalism and journalists in that process and what is the role of reader in supporting that journalism?”

best stocks to buy now: Unilife Corporation(UNIS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Unilife Corp (NASDAQ: UNIS) shares dropped 76 percent to $0.295. Unilife reduced its workforce by 51 employees and expects to record charge of $0.6 million.

best stocks to buy now: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

best stocks to buy now: Synacor, Inc.(SYNC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Synacor Inc (NASDAQ: SYNC) shares dropped 18 percent to $3.42. Synacor priced 5.715 million shares at $3.50 per share.

    Shares of Resources Connection, Inc. (NASDAQ: RECN) were down around 15 percent to $13.65 after the company posted downbeat quarterly results.

  • [By Monica Gerson]

    Synacor Inc (NASDAQ: SYNC) is projected to post a quarterly loss at $0.03 per share on revenue of $30.00 million.

    VAALCO Energy, Inc. (NYSE: EGY) is expected to post a quarterly loss at $0.11 per share on revenue of $18.59 million.

best stocks to buy now: Tile Shop Hldgs, Inc.(TTS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tile Shop Hldgs, Inc. (NASDAQ: TTS) shares dropped 23 percent to $15.68 after the company reported downbeat Q2 results.

    Shares of Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) were down 16 percent to $6.09 after the company posted disappointing quarterly earnings. Ericsson posted Q2 operating loss of 1.2 billion Swedish crowns ($145.3 million), versus a year-ago profit of 2.8 billion Swedish crowns.

Top 10 Casino Stocks For 2018

Last week Renewable Energy & Power, Inc. (OTC PINK : RBNW ), a diversified corporation with markets in energy-saving technologies of LED lighting, solar and wind energy, announced a large San Francisco Bay Area electronic assembly corporation has approved the installation of 1,275 LED lights for their entire main campus.

This is the third such announcement in as many months by the Las Vegas based company. It got me thinking about what the company does and how LED lighting can impact a business’ bottom line as much as it contributes to reducing emissions and the effects of global warming. But what about LED lights in RBNW’s backyard? How much of the Vegas Strip is LED? Well, it turns out, quite a bit.

Over a year ago three of Nevadas largest casino companies MGM Resorts, Wynn, and Las Vegas Sands announced plans to source renewable energy for their hotels, a move driven both by increasing demand for responsible energy use from the companies that rent their conference halls, and a surplus of cheap power from solar farms in Nevada and California. MGM Resorts had already implemented an ambitious energy conservation effort by replacing 1.3 million light bulbs in its properties with LEDs.

Top 10 Casino Stocks For 2018: CBOE Holdings Inc.(CBOE)

Advisors’ Opinion:

  • [By David Zeiler]

    Bats Global Markets was acquired on Feb. 28 by the Chicago Board Options Exchange (Nasdaq: CBOE).

    But the Bats BZX Exchange has had a bigger role than just serving as the place where the Winklevoss ETF will be listed…

  • [By David Zeiler]

    Bitcoin futures trading started at the CBOE Global Markets Inc. (Nasdaq: CBOE) on Dec. 10 and on the much larger CME Group Inc. (Nasdaq: CME) on Dec. 18. Nasdaq Inc. (Nasdaq: NDAQ) plans to begin trading Bitcoin futures in the first half of next year.

  • [By CNNMoney Staff]

    Stocks continued to rally despite the fact that options trading was temporarily halted Monday afternoon at exchanges run by CBOE Holdings (CBOE), Nasdaq OMX (NDAQ), BATS Global Markets and Miami International Holdings due to issues at the Options Price Reporting Authority (OPRA), which provides trading data and price quotes.

  • [By Wayne Duggan]

    Wall Street has been watching bitcoin this week, with the price up another 39.8 percent to above $16,000 ahead of the highly anticipated launch of bitcoin futures trading by Cboe Global Markets Inc (NASDAQ: CBOE) starting Sunday. Bitcoin has been around for years, but bitcoin futures trading will make trading a breeze for average retail investors for the first time.

Top 10 Casino Stocks For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Todd Campbell]

    Tesaro’s (NASDAQ:TSRO)ovarian cancer drug, niraparib, will begin competing for prescriptions earlier than expected. Niraparib, which will be sold under the brand name Zejula, notched FDA approval on Monday, more than three months ahead of its June 30 decision date. The early approval setsTesaro up for a fierce battle for market share withAstraZeneca (NYSE:AZN)and Clovis Oncology (NASDAQ:CLVS), both of which market drugs that work similarly to Zejula.

  • [By Ben Levisohn]

    Guggenheim’s Tony Butler and Kaitlin Sandor argue that Gilead Sciences (GILD) should buy Syndax Pharmaceuticals (SNDX), Corvus Pharmaceuticals (CRVS), and Tesaro (TSRO) to solve its problem of slowing sales:

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Casino Stocks For 2018: Valhi Inc.(VHI)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, basic materials shares slipped by 0.61 percent. Meanwhile, top losers in the sector included Valhi, Inc. (NYSE: VHI), down 13 percent, and LSB Industries, Inc. (NYSE: LXU), down 7 percent.

Top 10 Casino Stocks For 2018: ONEOK Inc.(OKE)

Advisors’ Opinion:

  • [By Matthew DiLallo]

    Energy infrastructure companies ONEOK (NYSE:OKE) and TransCanada (NYSE:TRP) are both emerging from the energy market downturn as stronger entities. Each made smart acquisitions, with TransCanada buying U.S. gas pipeline company Columbia Pipeline Group, while ONEOK is in the process of gobbling up its MLP,ONEOK Partners (NYSE:OKS). While these deals enhanced the growth profiles of both companies, TransCanada still stands out as the better buy for long-term income investors. Here’s why.

  • [By Garrett Cook]

    Citi maintains Buy ratings on Targa Resources (NYSE: TRGP), ONEOK (NYSE: OKE) and Oneok Partners (NYSE: OKS) citing the companies stories around natural gas liquids (NGLs).

Top 10 Casino Stocks For 2018: Gerdau S.A.(GGB)

Advisors’ Opinion:

  • [By Manikandan Raman]

    On the news, Freeport-McMoRan surged 12 percent to $10.20 and Lundin Mining climbed 12 percent to $3.33. Gerdau SA (ADR) (NYSE: GGB) rose 19 percent to $1.23, Vale SA (ADR) (NYSE: VALE) advanced 18 percent to $4.85 and Banco Bradesco SA (ADR) (NYSE: BBD) gained 11 percent to $7.15.

Top 10 Casino Stocks For 2018: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Top 10 Casino Stocks For 2018: URS Corporation(URS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Fidelty’s John Mirshekaritook a look at URS(URS) today at the Value Investing Congress.His takeaway: The stock could double in two years.

    Agence France-Presse/Getty Images

    His analysis started with URS’s use of its free cash. During the past, it hasn’t been pretty. They spent 6.3 billion on eight acquisitions, they’ve bought companies at valuations higher than own stock and return-on-equity has dropped from high teens to just 6%.

    The problem hasn’t been its business: Its return on tangible capital is 17%. Instead, the problem is that its management hasn’t maximized value through capital allocation. URS has lowest valuation: 9x 2013 cash earnings in its industry.

    Part of the problem: Management incentives are based on net income. This year, however, relative total shareholder return was added., something Mirshekari calls”a step in the right direction.” In May, URS filed an amended proxy which says it will look to change incentives from net income to return on equity and earnings per share. More importantly, it said acquisitions would end.

    If all goes right, URS could double in two years,Mirshekari says, comparing it to AECOM Technology (ACM).

    Looks a lot like AECOMM, which did something similar and rallied.

  • [By Ian Wyatt, Publisher & Chief Investment Strategist, Wyatt Investment Research]

    Fund manager John Mirshekari, of the Fidelity Low-Priced Stock Fund, recommended shares of URS (URS), an engineering and construction contractor.

Top 10 Casino Stocks For 2018: LaSalle Hotel Properties(LHO)

Advisors’ Opinion:

  • [By Marshall Hargrave]

    The other key benefit for Strategic is that it enjoys industry-leading earnings before interest, taxes, depreciation and amortization (EBITDA) per available room. For 2012, Strategic generated $81 per room of EBITDA. Compare this to top comps LaSalle Hotel (NYSE: LHO) at $74 per room and Pebblebrook Hotel Trust (NYSE: PEB) at $71. The reason for this is that Strategic is much less reliant than its peers on rooms, with much greater exposure to food and beverages. Strategic earns 53% of its revenue from rooms, while its peers get around 66% of revenues from rooms.

Top 10 Casino Stocks For 2018: Reinsurance Group of America, Incorporated(RGA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Morgan Stanley downgraded Chipotle (NYSE: CMG) to Equal-Weight.
    UBS downgraded AMC Networks (NASDAQ: AMCX) to Sell.
    Citi upgraded Sealed Air (NYSE: SEE) to Buy.
    Goldman Sachs upgraded Reinsurance Group (NYSE: RGA) to Buy.

  • [By David Sterman]

    My favorite insurers: AIG (NYSE: AIG) (which I discussed a few months ago), Protective Life (NYSE: PL) and Reinsurance Group of America (NYSE: RGA).

Top 10 Casino Stocks For 2018: Portola Pharmaceuticals, Inc.(PTLA)

Advisors’ Opinion:

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 30 percent to $20.08 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 14 percent to $20.96. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares dropped 23 percent to $21.92 after announcing Phase III Betrixaban results.

    Shares of Spark Energy Inc (NASDAQ: SPKE) were down 16 percent to $20.43. Spark Energy reported Q4 GAAP EPS of $(0.01) and adjusted EBITDA of $16.3 million.

  • [By Lisa Levin]

    Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares were also up, gaining 46 percent to $55.68 after the company disclosed that the FDA has approved Bevyxxa, a blood-thinner for acutely ill patients not undergoing surgery. BevyxXa is the first oral drug of its kind to be approved to help prevent deep vein thrombosis and pulmonary embolisms..

  • [By Todd Campbell]

    Portola Pharmaceuticals’ (NASDAQ:PTLA)could have two commercial-stage drugs on the market next year, but turning them into top-sellers will require a lot of money. Is Portola Pharmaceuticals’ balance sheet flush enough with cash to get its drugs across the finish line?

stock market guide

Gold on Tuesday pushed back above a closely watched, long-term average as investors grew jittery over the impending French presidential election, which could have a pair of antiestablishment candidates facing off for the top job.

June gold
GCM7, +0.96%
gained $7.90, or 0.6% at $1,261.60 an ouncetrading above its 200-day moving average of $1,260.65, which suggests positive momentum building in the yellow metal, if it closes above that level.

stock market guide: LKQ Corporation(LKQ)

Advisors’ Opinion:

  • [By Lisa Levin]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Wednesday's regular session.

stock market guide: eHealth Inc.(EHTH)

Advisors’ Opinion:

  • [By Lisa Levin]

    eHealth, Inc. (NASDAQ: EHTH) was down, falling around 32 percent to $9.53. eHealth reported a Q2 net loss of $0.5 million, versus a year-ago net income of $5.8 million. The company also reported weak quarterly revenue.

stock market guide: Ballard Power Systems, Inc.(BLDP)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of FuelCell Energy along withsmall cap alternative energy or fuel cell stocks like Ballard Power Systems Inc (NASDAQ: BLDP), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaking in 2014 with some signs of stabilization early last yearalong withsome increase this year:

  • [By Peter Graham]

    A long term performance chart shows shares of Plug Power plus alternative energy or fuel cell stock peers like Ballard Power Systems Inc (NASDAQ: BLDP), FuelCell Energy Inc (NASDAQ: FCEL) and Hydrogenics Corporation (NASDAQ: HYGS) all peaking in 2014 before collapsing with shares leveling off or perhaps finally to recover a bit:

  • [By Peter Graham]

    The Q4 2016 earnings report small cap fuel cell stock Ballard Power Systems Inc (NASDAQ: BLDP) is scheduled for before the market opens on Thursday (March 2nd).Small cap alternative energy or fuel cellstocks have notlived up to their hype, but Ballard Power Systems has been busy announcing the following news:

  • [By Lisa Levin]

    Friday afternoon, the non-cyclical consumer goods & services sector proved to be a source of strength for the market. Leading the sector was strength from Ballard Power Systems Inc. (USA) (NASDAQ: BLDP) and Sunoco LP (NYSE: SUN).

stock market guide: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

stock market guide: Burcon Nutrascience Corp(BUR)

Advisors’ Opinion:

  • [By William Romov]

    Last Wednesday (Dec. 6), the company received a patent for certain methods of production of its phase 2 antidepressant, AV-101.

    Penny Stock Current Share Price Dec. 4 – Dec. 8 Gain (as of Dec. 8)
    VistaGen Therapeutics Inc. (Nasdaq: VTGN) $1.80 135%
    FXCM Inc. (Nasdaq: GLBR) $1.12 124%
    Neuralstem Inc. (Nasdaq: CUR) $2.00 75.44%
    Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.49 75.29%
    ClearSign Combustion Corp. (Nasdaq: CLIR) $3.50 53.85%
    Astrotech Corp. (Nasdaq: ASTC) $4.21 51.99%
    Burcon NutraScience Corp. (Nasdaq: BUR) $0.72 44%
    LM Funding America Inc. (Nasdaq: LMFA) $3.72 42.53%
    Second Sight Medical Products Inc. (Nasdaq: EYES) $1.75 42.28%
    Globus Maritime Ltd. (Nasdaq: GLBS) $1.47 41.35%

    As a result, its share price shot up from $0.92 to $2.52 on Wednesday. The stock pulled back to $1.80 by the end of the week, for a total gain of 135% for the week.

stock market guide: Rhino Resource Partners LP(RNO)

Advisors’ Opinion:

  • [By Alexis Xydias]

    Investors are regaining confidence, squeezing pessimists who say the economy remains sluggish outside of Germany and point to record-low trading volume as a lack of conviction in the Euro Stoxxs 61 percent rally of the past two years. Besides gains in stocks from Banco Bilbao Vizcaya Argentaria SA to Renault SA (RNO), yields on Spanish and Italian bonds have declined to a two-year low compared with German bunds and the euro has strengthened 4.6 percent to $1.35 in the past six months.

Best Warren Buffett Stocks To Invest In 2018

The two biggest objections to investing in Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) are that it’s too large to earn good returns and that it depends too much on the stock-picking and company-acquiring skills of Warren Buffett and Charlie Munger, who are among the oldest executives running a major business today.

Will it ever earn as much as it did in the past?

I believe it can. When you understand the true nature of its returns those risks are not as big as they seem.

The first is certainly true in part. Buffett has said at times that if he was only managing $10m he could easily earn 50 – 70% per year through value investing and merger arbitrage.

Any investor who’s not happy with returns under 50% per year is in for some bad news. The real question is whether it can earn returns higher than an index fund.

Many investors believe that this is only possible as long as it’s run by Buffett and Munger. We don’t know how long that will be. If that happens to be another 10 or 20 years then it could still be a great opportunity. And if not?

Best Warren Buffett Stocks To Invest In 2018: OneBeacon Insurance Group, Ltd.(OB)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

Best Warren Buffett Stocks To Invest In 2018: Modine Manufacturing Company(MOD)

Advisors’ Opinion:

  • [By Monica Gerson]

    Modine Manufacturing Co. (NYSE: MOD) is projected to post its quarterly earnings at $0.32 per share on revenue of $351.33 million.

    Navios Maritime Holdings Inc. (NYSE: NM) is expected to report a quarterly loss at $0.37 per share on revenue of $101.51 million.

Best Warren Buffett Stocks To Invest In 2018: Firsthand Technology Value Fund, Inc.(SVVC)

Advisors’ Opinion:

  • [By Hibah Yousuf]

    Similarly, Twitter is also the biggest holding in the Firsthand Technology Value Fund (SVVC). With just over 1 million shares of the social media platform, Twitter represents nearly 11% of the total portfolio as of mid-year. Shares of Firsthand Technology Value jumped more than 6% Friday.

Best Warren Buffett Stocks To Invest In 2018: Pampa Energia S.A.(PAM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Friday afternoon, the utilities sector proved to be a source of strength for the market. Leading the sector was strength from Cia Energetica de Minas Gerais CEMIG-ADR (NYSE: CIG) and Pampa Energia S.A. (ADR) (NYSE: PAM).

  • [By Lisa Levin]

    On Tuesday, utilities shares slipped by just 0.5 percent. Meanwhile, top gainers in the sector included Pampa Energia S.A. (ADR) (NYSE: PAM), up 2 percent, and Chesapeake Utilities Corporation (NYSE: CPK) up 3 percent.

Best Warren Buffett Stocks To Invest In 2018: Broadcom Corporation(BRCM)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Susquehanna reported on Tuesday that it has raised its rating on Broadcom Corporation (BRCM).

    The firm has upgraded BRCM from “Neutral” to “Positive,” and has lifted the company’s price target from $33 to $35. This price target suggests a 23% upside from the stock’s current price of $26.91.

    Analyst Chris Caso commented: “Our downgrade of BRCM in May was predicated on already high Street expectations on handsets and no notable improvement in networking to drive upside. We think expectations and the stock price have now been sufficiently reset ahead of what we expect to be catalysts in 2014 including the iPhone 6 product cycle, potential improvement in networking and the impact from the recent Renesas acquisition. In addition, after several years of overspending on their handset initiatives, we think we are now closer to the point where the company either captures a return on that investment or is forced to moderate spending either of which benefit profitability. We see the upcoming December analyst meeting as a potential intermediate catalyst.”

    Broadcom shares were up 38 cents, or 1.41%, during pre-market trading Tuesday. The stock is down 19% YTD.